Argenx, NL0010832176

Argenx stock heads pre-market after a 0.02 percent drop

Published on 09/16/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 15, 2026, Argenx stock ended at USD 1,001.50 on Nasdaq, down 0.02 percent. The stock underperformed the Nasdaq Composite, which fell 0.78 percent to 25,981.57.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund
Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock closed at USD 1,001.50 on Nasdaq on September 15, 2026, down 0.02 percent. The move came against a weaker US tape, with the Nasdaq Composite ending at 25,981.57, down 0.78 percent.

September 15, 2026 in numbers

Argenx SE (ISIN NL0010832176, Nasdaq: ARGX) finished the session in a narrow range after trading between USD 986.26 and USD 1,013.84, according to the market overview cited by ad hoc news. That session range kept the close well inside the day band and left the stock only slightly below the previous Nasdaq close.

In the same market note, ad hoc news said Jefferies kept its Buy rating and USD 1,215 target on the shares. The note also pointed to the Nasdaq close of USD 1,001.50, which sat 17.6 percent below that target.

Pre-market on September 16, 2026

Argenx appears at Morgan Stanley's 24th Annual Global Healthcare Conference, where management presented on September 14, 2026, as reported by ad hoc news. Jefferies' Buy call and USD 1,215 target also stay in view after the latest note from the same outlet.

Disclaimer...

en | NL0010832176 | ARGENX | boerse | 70109003 | bgmi